Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced ...

The Biden administration will propose a new rule to ban credit score companies from considering medical debt when they compile Americans' credit reports. The company expects to deliver $120 to $140 ...

AstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, worth up to $6 billion. The deal covers DS-1062, Daiichi Sankyo’s proprietary antibody-drug ...

Chart does not reflect overnight price.

Nasdaq Dividend History provides straightforward stock’s historical dividends data. Dividend payout record can be used to gauge the company's long-term performance when analyzing individual stocks.

Version 1.0 has been frozen and at this time is undergoing public review. Version 1.0 is considered stable enough to begin developing toolchains, functional simulators, and implementations, including ...